戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 1200 mg or chemotherapy (physician's choice: vinflunine 320 mg/m(2), paclitaxel 175 mg/m(2), or 75 mg
2                                              Vinflunine 320 mg/m2 by 10-minute intravenous infusion w
3  at the mitotic IC(50) value was highest for vinflunine (4.2 +/- 0.2 microM), intermediate for vinore
4 study reports the clinical efficacy data for vinflunine, a novel microtubule inhibitor, in MPM.
5                                              Vinflunine, a novel vinca alkaloid, showed some activity
6 -generation Vinca alkaloids, vinorelbine and vinflunine, affect microtubule dynamics very differently
7  Thus the unique constellation of effects of vinflunine and vinorelbine on dynamic instability and tr
8                         The major effects of vinflunine and vinorelbine on dynamic instability were a
9         Here we have analyzed the effects of vinflunine and vinorelbine on microtubule dynamic instab
10 latively less powerful inhibitory effects of vinflunine and vinorelbine on microtubule dynamics bette
11                                 In addition, vinflunine and vinorelbine suppressed treadmilling, but
12 ifluoro-3',4'-dihydrovinorelbine (F12158, or vinflunine) and the parent compound, vinorelbine.
13                                              Vinflunine can be delivered with high-dose intensity in
14 axation times for polymer redistribution for vinflunine consistent with induction of the shortest spi
15                                              Vinflunine demonstrates 3-16-fold lower overall affinity
16 ntation velocity to compare vinorelbine- and vinflunine-induced self-association of porcine brain tub
17                                              Vinflunine is a novel Vinca alkaloid presently in Phase
18 ovides the only direct evidence to date that vinflunine is a tubulin-binding drug.
19 entirely consistent with our hypothesis that vinflunine is likely to result in reduced clinical neuro
20 eservoir(s) may be partially responsible for vinflunine's high efficacy and minimal side effects.
21                      These data suggest that vinflunine should be further evaluated in the management
22 shortening in vitro, whereas vinorelbine and vinflunine suppress the rate and extent of microtubule g
23 or inhibition of HeLa cell proliferation for vinflunine, vinorelbine, and vinblastine were 18, 1.25,
24 ng immune cells [IC2/3]), chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), an

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。